XML 15 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Feb. 13, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Trading Symbol HRTX    
Entity Registrant Name HERON THERAPEUTICS, INC. /DE/    
Entity Central Index Key 0000818033    
Current Fiscal Year End Date --12-31    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Accelerated Filer    
Entity Well-known Seasoned Issuer No    
Entity Common Stock, Shares Outstanding   152,329,588  
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity File Number 001-33221    
Entity Tax Identification Number 94-2875566    
Entity Address, Address Line One 100 REGENCY FOREST DRIVE    
Entity Address, Address Line Two SUITE 300    
Entity Address, City or Town CARY    
Entity Address, State or Province NC    
Entity Address, Postal Zip Code 27518    
City Area Code 858    
Local Phone Number 251-4400    
Entity Interactive Data Current Yes    
Entity Incorporation, State or Country Code DE    
Document Annual Report true    
Entity Public Float     $ 394.1
Document Transition Report false    
Title of 12(b) Security Common Stock, par value $0.01 per share    
Security Exchange Name NASDAQ    
Auditor Name WithumSmith+Brown, PC    
Auditor Location Orlando, Florida    
Auditor Firm ID 100    
Documents Incorporated by Reference

Portions of the registrant’s Definitive Proxy Statement related to its 2025 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. Such Definitive Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates. Except as expressly incorporated by reference, the registrant’s Definitive Proxy Statement shall not be deemed to be part of this report.

    
Auditor Opinion [Text Block]

Opinion on the Consolidated Financial Statements and Internal Control Over Financial Reporting

We have audited the accompanying consolidated balance sheets of Heron Therapeutics, Inc. and subsidiaries (the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations and comprehensive loss, stockholders’ equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively referred to as the "consolidated financial statements"). We also have audited the Company’s internal control over financial reporting as of December 31, 2024, based on criteria established in 2013 Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in 2013 Internal Control—Integrated Framework issued by the COSO.